Ozempic Significantly Reduces Risks in Kidney Disease and Diabetes, Study Shows
TL;DR Summary
Novo Nordisk's semaglutide significantly reduced the risk of major cardiovascular events and death in patients with type 2 diabetes and chronic kidney disease in a Phase 3 study, supporting its potential for broader indications. The results were presented at the European Renal Association's conference and published in the New England Journal of Medicine.
Topics:top-news#cardiovascular-events#chronic-kidney-disease#health#novo-nordisk#phase-3-trial#semaglutide
- Novo’s semaglutide hits secondary endpoints in Ph3 kidney disease trial, cutting risks of cardio events and death Endpoints News
- Ozempic May Help Treat Kidney Disease, Study Finds The New York Times
- Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds CNN
- Novo unveils full results from its GLP-1 trial in CKD FiercePharma
- Ozempic Slows Kidney Disease, Novo Nordisk Study Finds The Wall Street Journal
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
50%
105 → 53 words
Want the full story? Read the original article
Read on Endpoints News